Switzerland· 68626001
Condromed 200 mg / 250 mg, Hartkapseln
A other specific antirheumatic agents product, registered in Switzerland by IBSA Institut Biochimique SA and dispensed under Swissmedic category B. The same ATC class is registered in 3 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Condromed is registered in 3 of 19 countries.
Countries holding a registration under ATC M01CX (other specific antirheumatic agents), each read from that country’s own register.
- This record: Switzerland
- 3 of them publish a price we can compare per daily dose
Condromed · ATC M01CX
3 / 19 countries
- Finlandprice
- Polandprice
- Switzerlandprice
The record
At a glance
- Manufacturer
- IBSA Institut Biochimique SA
- Country
- Switzerland (CH)
- ATC code
- M01CX
- ATC class
- Other specific antirheumatic agents
- Swissmedic category
- B
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under M01CX
Other specific antirheumatic agents, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0178bb7-9e0f-4578-870a-0d1c5d513b6b GET /v1/drugs/c0178bb7-9e0f-4578-870a-0d1c5d513b6b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about Condromed.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.